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Abstract 
Urate is the terminal product of purine metabolism in primates, including humans. Urate is also an 
efficient scavenger of oxidizing species and is thought to be an important antioxidant in human body 
fluids. Allantoin, the major oxidation product of urate, has been suggested as a candidate biomarker of 
oxidative stress because it is not produced metabolically. Although urate is converted to allantoin under 
strongly alkaline pH, such conditions have been used in the past to facilitate extraction of allantoin. We 
evolved a method for the determination of allantoin concentrations in human plasma and serum by gas 
chromatography-mass spectrometry without such artifact. With this method, we show that alkaline 
conditions do indeed cause breakdown of urate, leading to significant overestimation of allantoin 
concentration in human samples. By using our alternative method, serum samples from 98 volunteers 
were analyzed, and allantoin levels were found to be significantly lower than was previously reported. The 
in vivo utility and sensitivity of our method was further evaluated in human nasal-lining fluids. We were 
able to demonstrate an ozone-induced increase in allantoin, in the absence of increases in either 
ascorbate or glutathione oxidation products. © Copyright 2009, Mary Ann Liebert, Inc. 2009. 
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Allantoin in Human Plasma, Serum, and Nasal-Lining Fluids
as a Biomarker of Oxidative Stress: Avoiding Artifacts
and Establishing Real in vivo Concentrations
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Annelie Behndig,5 Katherine Kasiman,2 Chung-Yung J. Lee,1 Raymond C.S. Seet,6 Wenxia Zhang,1
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Abstract
Urate is the terminal product of purine metabolism in primates, including humans. Urate is also an efficient
scavenger of oxidizing species and is thought to be an important antioxidant in human body fluids. Allantoin, the
major oxidation product of urate, has been suggested as a candidate biomarker of oxidative stress because it is not
produced metabolically. Although urate is converted to allantoin under strongly alkaline pH, such conditions
have been used in the past to facilitate extraction of allantoin. We evolved a method for the determination of
allantoin concentrations in human plasma and serum by gas chromatography–mass spectrometry without such
artifact. With this method, we show that alkaline conditions do indeed cause breakdown of urate, leading to
significant overestimation of allantoin concentration in human samples. By using our alternative method, serum
samples from 98 volunteers were analyzed, and allantoin levels were found to be significantly lower than was
previously reported. The in vivo utility and sensitivity of our method was further evaluated in human nasal-lining
fluids. We were able to demonstrate an ozone-induced increase in allantoin, in the absence of increases in either
ascorbate or glutathione oxidation products. Antioxid. Redox Signal. 11, 1767–1776.
Introduction
Urate is generated during purine metabolism via theoxidation of hypoxanthine and xanthine by xanthine
oxidase (EC 1.14.21.1), but it cannot be further oxidized en-
zymatically in the human body and so accumulates to high
levels in body fluids. Ames et al. (2) revealed that urate is a
scavenger of hydroxyl radicals, hemoglobin-derived oxidiz-
ing species, and singlet oxygen in vitro. Urate has in vitro an-
tioxidant activity against several reactive oxygen, nitrogen,
and chlorine species (2, 3, 14, 30, 33, 34). As much as 60% of the
total free radical scavenging capacity of human plasma has
been attributed to urate, making urate potentially an impor-
tant antioxidant in human body fluids (32). Attack of a range
of reactive species on urate produces allantoin, which has
therefore been suggested as a biomarker for oxidative stress
(13, 19).
Prior methods for the detection of allantoin in samples of
human body fluids are based on alkaline hydrolysis of al-
lantoin to allantoate, followed by acid hydrolysis of allantoate
to glyoxylic acid and urea. Glyoxylic acid in turn forms the
chromophore glyoxylate 2,4-dinitrophenylhydrazone when
incubated with 2,4-dinitrophenylhydrazine (Rimini-Schryver
reaction), which can be quantified spectrophotometrically or
with high-performance liquid chromatography (HPLC) (13).
The accuracy of methods based on this procedure is critically
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dependent on the removal of urate and glyoxylic acid during
sample cleanup (18, 20, 21, 23). Furthermore, lack of inter-
nal standards can make these methods sensitive to volume
changes potentially caused by evaporation during sample
derivatization (20). More recently, a gas chromatography–
mass spectrometry (GC=MS) method, originally developed
for the quantification of allantoin in animal urine (8), has been
modified for use with human samples (29). Several clinical
investigations have used related GC=MS methods to quanti-
tate allantoin levels (10, 29, 35–37) but this method is not yet
widely used because of the lack of analytic validation of some
of the techniques. Direct chromatography as well as complex
enzyme-cycling methods have also been proposed (5, 7).
Because of its polar character, allantoin is not retained well
during reverse-phase chromatography or by using most solid-
phase extraction (SPE) technologies. To overcome this prob-
lem, strongly alkaline conditions (either 50 mM NaOH or 6 M
NH4OH) are often used (8, 29). Although these alkaline con-
ditions facilitate retention of allantoin on anion-exchange
matrices, urate is unstable at high pH and can be oxidized to
allantoin (11, 19). However, the extent to which this arti-
fact might affect measurement of allantoin in body fluids is
uncertain.
Here we reveal that the artifact is significant, describe a
method to avoid it during isotope-dilution GC=MS determi-
nation of allantoin in plasma and serum samples, establish
a true reference range for allantoin levels in human serum,
compare the measurement of allantoin with that of F2-
isoprostanes as a biomarker of oxidative stress, and illustrate
the use of allantoin measurements to measure oxidative stress
in human nasal-lining fluids (NLFs) during a controlled ex-
posure to ozone.
Materials and Methods
Materials
All chemicals were obtained from Sigma-Aldrich (St. Louis,
MO), unless otherwise stated. Allantoin was from Fluka. So-
dium hydroxide and acetonitrile (HPLC grade) were from
Merck AG (Darmstadt, Germany). [1,3-15N2] urate was from
Cambridge Isotope Laboratories (MA), and Allantoin-U-15N4
50% was from Icon Isotopes (NJ).
Preparation of 15N-labeled allantoin standard
Heavy isotope–labeled allantoin for use as internal stan-
dard was prepared by digesting [1,3-15N2] urate with excess
uricase from Bacillus fastidious (Fluka) by following the pro-
cedure reported by Chen et al. (8) with slight modifications. In
brief, 50 ml of 1 mM [1,3-15N2] urate stock solution was pre-
pared in 0.25 mM sodium hydroxide (NaOH) and incubated
at 378C in the presence of 0.5 U of uricase. [15N]-labeled al-
lantoin was purified by preparative HPLC on an Agilent 1100
Series prep HPLC system equipped with a 250-mm Agilent
Zorbax SB-C18 Prep HT (7 mm) column. The purity of the
[15N]-labeled allantoin standard was assessed with HPLC to
be >95% (data not shown). The identity of the [15N]-labeled
allantoin derivatives was confirmed with GC=MS.
Quantification of allantoin by isotope dilution
During the derivatization of allantoin with N-methyl-
N-(tert-butyldimethylsilyl) trifluoroacetamide (MTBSTFA),
three silicon-containing tert-butyldimethylsilyl (TBDMS)
groups are added to each molecule of allantoin (8). Silicon has
two stable and relatively abundant heavy isotopes [29Si (þ1)
and 30Si (þ2); 4.67% and 3.1% abundance, respectively]. The
addition of heavy isotopes of silicon during derivatization
causes part of the allantoin signal (398 m=z) to be shifted to
higher mass numbers. The resulting nonlinearity of the cali-
bration curve does not affect the quantification of allantoin by
stable isotope dilution (8, 29).
Allantoin sample extraction and derivatization
Our GC=MS method was modified from that of Chen et al.
(8). Internal standard (25 ml of 13 mM [15N]-labeled allantoin)
was added to 25 ml of either aqueous allantoin standards,
human plasma, serum, or human nasal-lavage fluid (NLF)
samples. Spiked samples were simultaneously deproteinized
and extracted by addition of 100ml of acetonitrile followed by
thorough vortexing of samples. Samples were then centri-
fuged (20,000 g, 48C, 5 min), and supernatants were dried
under N2. After drying, 50ml of MTBSTFA in pyridine (1:1
vol=vol) was added, and the derivatization reaction was fa-
cilitated by incubation at 508C for 2 h.
Allantoin GC=MS instrumentation and analysis
We used a Hewlett–Packard 6890 gas chromatograph
(Agilent Technologies, CA) connected to a HP5973 mass se-
lective detector. The injection port was kept at 2508C and the
GC=MS interface temperature was 2908C. Separations were
performed on an Agilent Ultra 2 fused silica capillary column
(12 m length, 0.2 mm internal diameter). Helium was used as
the carrier gas at a flow rate of 1 ml=min. Derivatized product
(1 ml) was injected in splitless mode. Initial column tempera-
ture was 1008C and was increased rapidly (408C=min) to
1508C. Column temperature was then increased to 1988C at a
rate of 48C=min. Finally, the column temperature was in-
creased to 3008C at a rate of 308C=min, and this temperature
was held for another 2 min. Ions were generated by using the
electron-ionization mode at 70 eV, with the ion source main-
tained at 2308C.
Sample preparation using alkaline SPE
for evaluation of extraction artifacts
The method of Pavitt et al. (29) was used with modifica-
tions. In brief, allantoin standards, urate standards, or plasma
samples (100ml) were spiked with 100 ml of 13 mM [15N]-
labelled allantoin standard and diluted with 900 ml of H2O.
Samples were made alkaline by addition of 50ml of 1 M
aqueous NaOH and applied to preequilibrated Waters Oasis
MAX-SPE cartridges (Oasis Water Corp., MA). Columns were
washed 3 times with 1 ml of water followed by one wash with
1 ml of methanol, and allantoin was eluted by using 1 ml of 0.8
M acetic acid in pure methanol. Samples were dried under N2,
derivatized, and analyzed as described earlier.
NaOH incubation
Pure standards containing 400 mM urate were prepared in
10 mM Tris at pH 7.5. Urate standards or plasma samples
(25 ml) were spiked with 25 ml of [15N]-labelled allantoin in-
ternal standard and diluted with 250 ml of water. Samples
were incubated for 10 min at room temperature after addition
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of 12.5 ml of 1 M aqueous NaOH. Incubations were stopped by
addition of 1 ml of 0.8 M acetic acid in methanol.
Preparation of partially lysed plasma samples
For the in vitro comparison of sensitivity and correlation
between allantoin and total F2-isoprostanes (freeþ esterified)
in human plasma samples, we recruited eight volunteers (four
male, four female subjects) younger than 40 years (mean age,
31.8 4.7 years). Before enrollment, all subjects gave informed
consent in accordance with the approval granted by the In-
stitutional Review Board of the National University Hospital,
Singapore. Subjects were required to fast for at least 8 h before
blood collection. Blood samples (10 ml) were collected in Na-
EDTA–coated vacutainer tubes. Plasma was prepared from
one tube by centrifugation at 3,000 rpm for 10 min at 48C,
15 ml of 5 mM indomethacin (in ethanol) per 1 ml plasma, and
20 ml per 1 ml plasma of 2 mM BHT (in ethanol) was added,
and samples were stored at 808C until used for analysis.
Great care was taken to avoid any degree of lysis in these
plasma samples. A second vacutainer was frozen immedi-
ately without first removing blood cells, leading to rupture of
blood cells (fully lysed blood). For each volunteer, we then
prepared plasma samples representing seven different de-
grees of lysis by mixing unlysed plasma with 0, 0.5, 1, 5, 10, 15,
and 20% fully lysed blood from the same volunteer. Samples
were mixed, incubated at room temperature for 20 min, and
subsequently stored at808C until determination of allantoin
and total F2-isoprostanes.
Urate determination
Urate concentrations were determined with HPLC with UV
detection. Samples (30 ml) were diluted with water to a final
volume of 150ml. Diluted samples were filtered through a
centrifugal molecular-weight cut-off spin-filter device (Na-
nosep; 10 kDa MWCO). The deproteinized filtrate was di-
rectly injected into an Agilent Series 1100 analytic HPLC
system connected to a 250-mm Zorbax SB-C8 (5mm) analytic
column. The mobile phase was 2 mM NH4H2PO4 at pH 2.95
(isocratic, 1 ml=min flow). Urate was monitored at 293 nm by
using a diode array detector. Under these conditions, urate
eluted at *7 min and was not confounded by other serum
constituents. Each sample was injected 3 times, and the peak
area averaged. A zero to 400 mM standard curve, prepared
from pure urate samples, was used for quantification. NLF
urate and allantoin determinations were made in samples
(400 ml) pretreated with 700 ml of 15 mM ethylenediaminete-
traacetic acid.
Glutathione and glutathione disulfide determination
Glutathione and glutathione disulfide concentrations in
recovered NLF were determined by using the glutathione
disulphide reductase-dithiobisnitro-benzoic acid recycling
assay, as previously described (27).
Ascorbate and dehydroascorbate determination
Ascorbate and total vitamin C determinations were made
on nasal-lavage samples pretreated with the metal chelator
desferrioxamine mesylate (DES) and the synthetic antioxidant
butylated hydroxytoluene (BHT) on collection, as previously
described (24), before storage at 808C. On the day of anal-
ysis, samples were thawed on wet ice and acidified with
metaphosphoric acid (final concentration, 5%) and lipid ex-
tracted with heptane, before analysis with reverse-phase
HPLC with electrochemical detection (400 mV, 100 nAmp)
(17). Determination of the total vitamin C pool was performed
after sample preincubation with the reductant dithiothreitol
at a final concentration of 0.2% (1 h at room temperature),
before sample acidification and lipid extraction as outlined
earlier (12). The concentration of dehydroascorbate (DHA) in
samples was calculated by subtracting the ascorbate concen-
tration from that of the determined total vitamin C pool.
Determination of F2-isoprostanes levels
Samples were extracted and derivatized by using a previ-
ously described method (22). In brief, before analysis, the
plasma samples were thawed at room temperature. Mixed
heavy isotopes, 8-iso-PGF2a-d4 and IPF2a-VI-d4, all prepared
in ethanol, were added to plasma and mixed. Plasma (1 ml)
was hydrolyzed at 378C for 30 min with 1 ml of 1 M potassium
hydroxide prepared in methanol for the release of esterified
lipids. Methanol, 5 M HCl, and 40 mM formic acid (pH 4.6)
were added and mixed. The samples were extracted and de-
rivatized as follows. MAX SPE (Oasis Water Corp.,) car-
tridges were used to purify the prepared samples, by washing
with 2% ammonium hydroxide and then by methanol: 20 mM
formic acid (pH 4.6) mix (40:60 vol=vol), hexane, and hex-
ane:ethyl acetate (70:30 vol=vol). Thereafter, hexane:
ethanol:acetic acid (20:29.4:0.6 vol=vol) was loaded into the
cartridge and collected for total F2-IsoPs analysis.
Samples were then dried under ultrahigh-purity nitrogen
gas, derivatized with DIPEA and PFBBr at room temperature
for 30 min and dried again under nitrogen gas. Afterward,
acetonitrile and BSTFA with 1% TMCS were added and in-
cubated at room temperature for 2 h. The derivatized samples
were then dried and reconstituted in iso-octane and incubated
at room temperature for 20 min for GC-MS analysis (Hewlett-
Packard 5973N and 6890; Agilent Technologies).
Volunteers and study design
For serum baseline determination, 98 volunteers (49 male, 49
female subjects) were included in the serum baseline study.
Volunteers were aged between 40 and 96 years, with a me-
dian age of 65.5 (mean, 64.4 12.4) years. Demographics such
as age, gender, ethnicity, and education were collected, as well
as health indicators such as weight, height, and physical activ-
ity. Before enrollment, all subjects gave informed consent in
accordance with the approval granted by the local Ethics Board
(Domain Specific Review Board, Singapore). Subjects were
required to fast for at least 8 h before serum collection.
Human nasal-lavage samples for the determination of al-
lantoin were obtained from a double-blinded, crossover con-
trol ozone challenge study performed at the University
Hospital of Northern Sweden, Umeå (24). In this study 15
healthy subjects (seven male, eight female subjects; mean age,
24 2.6 years), all nonsmokers with no preexisting allergic or
respiratory disease, were exposed on three separate occasions,
once to filtered air, and twice to 0.2 ppm of ozone for 2 h, with
separate exposures at least 3 weeks apart. Ozone exposures
were performed after either a 7-day treatment with a vitamin
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C and E cosupplement [500 mg vitamin C, 100 mg vitamin E,
(RRR)-a-tocopherol acetate] or a placebo compound, with the
final tablet taken with the subject’s breakfast 1 h before en-
tering the exposure chamber. Full details of the exposure
protocol and exposure setup were published previously (24).
Nasal-lavage baseline samples were obtained from subjects
immediately before entering the chamber, 1 h into the actual
exposure (1h-E), immediately after the 2-h exposure (0 h after
exposure, 0h-PE), and 6 h after the end of the challenge (6 h
after exposure, 6h-PE). Informed consent was obtained from
each volunteer, and the Ethics Committee of Umeå University
approved the study in accordance with the Declaration of
Helsinki.
Samples for allantoin determination in biologic fluids
The method was initially validated for both plasma and
serum samples by using pooled reference samples. Initial
method development and in vitro evaluation of extraction
artifacts used pooled samples kept in the laboratory for the
purpose of quality control and method development. Eva-
luations of clinical baseline levels, detection limits, spike
recovery, and precision were carried out by using serum
samples collected from healthy volunteers (see earlier). Serum
samples were collected into 10-ml serum-separator tubes.
Separation of serum from blood cells was achieved by cen-
trifugation at 2,000 g at 48C for 10 min. Samples were stored at
808C before analysis.
Nasal-lavage samples were collected by using the metered
nasal-spray method (25). In brief, five 100.1-ml volumes
of 0.9% saline were sprayed into each nostril. The recov-
ered material was pooled and transferred into a sterile plastic
receptacle maintained on wet ice. The lavage was self-
administered by the subject after demonstration of the proce-
dure, with the aspirates collected after each 1-ml instillation to
limit the instilled volume and dwell time of the saline in the
nose. In total, the protocol took *2 min per nostril, with a
total instilled volume of 10 ml. The recovered aspirate was
filtered through a sterile 100-mm pore nylon filter to remove
mucus aggregates before centrifugation at 400 g at 48C for
15 min to isolate the cell-free fraction. Nasal-lavage samples
for the determination of urate and allantoin were treated the
metal (Chelator EDTA): 0.4 ml of lavage, plus 0.7 ml 1.5 mM
EDTA, before storage at 808C.
Statistical analysis
Data were analyzed by using SPSS for Windows (SPSS Inc.,
Chicago, IL) and the R software environment for statistical
computing and graphics (R Foundation for Statistical Com-
puting, Wien, Austria). Serum allantoin values were not nor-
mally distributed (Shapiro–Wilk normality test); therefore,
data are presented as median (5–95% percentiles), unless
otherwise specified. Serum urate data were normally distrib-
uted and are therefore summarized as means with standard
deviations. All antioxidant and oxidation marker concentra-
tions in NLF were nonparametric and are hence expressed
throughout as median concentrations with the interquartile
range. Significant-difference testing was performed by using
the Mann–Whitney U test at p< 0.05 or Student’s t test for all
unpaired data. For the NLF in which data were paired, com-
parisons between the groups were performed by using the
Wilcoxon signed-rank test.
Results
Assay development
Despite extensive testing of reverse-phase and ion-
exchange materials, allantoin was not retained satisfactorily
on any of the SPE matrices tested unless alkaline conditions
were used (data not shown). We therefore developed a
modified GC=MS procedure that allowed us to avoid SPE
entirely. Samples were spiked with [15N]-labelled allantoin as
internal standard, extracted into acetonitrile, and dried under
N2 for analysis with GC=MS. The detection limit (the con-
centration at which the peak area exceeded the baseline noise
by at least a factor of 10) was determined in human serum by
using allantoin-U-15N4 (yielding a triply labeled ion with an
m=z of 401) to be <2 pmol (data not shown). When applied to
FIG. 1. Quantification of allantoin by isotope dilution.
Peaks of endogenous allantoin from extraction of 25 ml of
human serum (A) and nasal lavage fluids (B) without alka-
line solid phase extraction. Quantifier ion at 398 m=z (solid
line) and internal standard ion at 400 m=z (dotted line) are
shown.
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pooled serum, plasma, or nasal-lavage samples from healthy
subjects, our method yields clearly detectable concentrations
of allantoin, and the selective ion chromatogram is free of
confounding peaks (Fig. 1). Total variability and within-run
variability were determined in pooled serum samples at low
(1.2 mM), medium (2.4 mM), and high (14.6 mM) concentra-
tions. This concentration range spans the majority of the
clinical serum data observed (see later). Repeated data were
collected in accordance with National Committee on Clinical
Laboratory Standards (NCCLS) protocol EP5-A2 (28). The
data showed acceptable inter- and intraday variabilities over
the 20-day test period (Table 1).
It was previously suggested that salts, such as potassium
phosphate and sodium acetate, can interfere with allantoin
quantification (8). However, when serum samples were
spiked with 1, 2.5, and 5mM allantoin, we were able to
quantitate accurately the allantoin spike levels in each case,
even in the presence of relatively high endogenous allantoin
levels, without the need for desalting. Recovery of spiked al-
lantoin over this concentration range was *95% (Table 1).
Assessment of artifactual conversion of urate
to allantoin in previous alkali-based methods
First, we subjected analytic grade urate standards either to
SPE in the presence of NaOH or to our modified GC=MS
procedure, avoiding alkaline conditions. With our method,
allantoin concentrations in pure urate standards (400 mM) are
very low [0.27 0.03 mM (n¼ 3)]. However, after the alkaline
SPE procedure for allantoin extraction, levels of 13.5 0.5 mM
(or 3.38% urate) were detected in the urate standards. This
increase in allantoin during SPE is associated with a decrease
in urate from 399 2mM before alkaline extraction to 381
2 mM after SPE. The increase in allantoin of 13.5 0.5 mM
therefore is associated with a comparable loss of urate of
about 18 4 mM. This result is consistent with artifactual
in vitro conversion of urate to allantoin. We also incubated
human blood plasma with or without 50 mM NaOH, by using
the same conditions used to facilitate binding of allantoin
during SPE, and found that addition of NaOH to a final
concentration of 50 mM was sufficient to increase allantoin
concentrations from 2.4 to 14 mM. This suggests that the
NaOH concentrations used during SPE of allantoin from
plasma and serum in former methods can convert significant
amounts of urate to allantoin. To confirm this, we used
[1,3-15N2] urate spiking of plasma. When [1,3-
15N2] urate is
oxidized to allantoin, heavy [15N]-labeled allantoin is pro-
duced, which is not normally present in the human body.
Plasma samples spiked with [1,3-15N2] urate equivalent to
200, 300, or 400mM were analyzed by using either our method
or the reference GC=MS method, including alkaline SPE
conditions. The SI-isotope–corrected 400–398 m=z ion ratio
is calculated by subtracting 0.1523 from the experimentally
observed ion ratio (8, 29). A corrected 400–398-m=z ion ratio
larger than zero indicates conversion of the spiked [1,3-15N2]
urate to [15N]-labelled allantoin.
When [1,3-15N2] urate–spiked plasma samples were sub-
jected to the alkaline SPE procedure, we found that the cor-
rected ion ratio increased nonlinearly with the concentration
of spiked [1,3-15N2] urate (Fig. 2). When plasma was spiked
with high, but physiologically relevant levels of [1,3-15N2]
urate (equivalent to 400 mM plasma urate), the corrected
400–398 m=z ion ratio was *1.3. This indicates that under
these conditions, the amount of 15N-labelled allantoin pro-
duced by artifactual conversion of [1,3-15N2] urate exceeded
the total amount of unlabelled endogenous allantoin in the
sample. No [15N]-labelled allantoin was detected when alka-
line SPE conditions or spiking with [1,3-15N2] urate was
omitted (Fig. 2).
Comparison of allantoin and F2-isoprostanes
as marker of in vitro oxidative damage
To compare the utility of allantoin as a marker of oxida-
tive damage with that of an established biomarker of oxida-
tive damage, we used a simple in vitro paradigm of oxidative
stress in human plasma. Hemoglobin in the presence of H2O2
has long been used to induce elevated levels of oxidative lipid
peroxidation and is known to be capable of oxidizing urate
with the formation of allantoin (2). However, even in the ab-
sence of added H2O2, free hemoglobin favors peroxidation
when added to lipid-containing systems (15).
To test the sensitivity of allantoin relative to a well-estab-
lished and widely used marker of lipid oxidation, total F2-
isoprostanes, we therefore chose to investigate the degree of
correlation between total F2-isoprostanes and allantoin levels
after incubation of plasma samples with increasing amounts
of hemoglobin in the form of lysed whole blood. As expected,
we found that with increasing amounts of hemoglobin, both
total F2-isoprostanes and allantoin levels are robustly ele-
vated [maximum *300% and 700% of baseline, respectively
(Fig. 3)]. We further found that, although a significant amount
of scatter occurs, a moderately good correlation exists be-
tween total F2-isoprostanes and allantoin over the whole
range of conditions tested (Pearson correlation coefficient,
0.69; p< 0.0001).
Table 1. Assay Variability and Recovery
Precision
sample Low Medium High
N (repeated days) 20 20 20
Conc. (mM) 1.19 2.43 14.60
Total precision
SD 0.195 0.365 0.972
CV 16.4% 15.0% 6.7%
Within-run
SD 0.123 0.10 0.525
CV 10.3% 4.1% 3.6%
Spike recovery
Spike (mM) Observed (mM) Recovery (%)
0 5.35 0.02
1 6.56 0.03 121.0
2.5 7.70 0.02 93.9
5 10.11 0.01 95.3
Average recovery 103.4 15.3
Variability data were collected by using pooled serum samples at
high, medium, and low concentrations. Two repeated runs of two
aliquots each were analyzed daily for each of the three concentrations
for determination of total and within-run variability in accordance
with NCCLS guidelines. Spike recovery at each of three spike levels
was determined for three independent samples.
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Baseline serum allantoin concentrations
in human volunteers
We obtained fasting blood samples from 98 volunteers
aged between 40 and 96 years. Baseline serum concentrations
of allantoin in this cohort irrespective of gender were me-
dian 2.36 mM with 5–95% percentiles (0.85–7.95) mM. A sta-
tistically significant trend to lower allantoin concentrations
was found in women 2.18 (0.76–9.26) mM relative to men 2.77
(0.92–8.25) mM ( p¼ 0.032, Mann–Whitney U test). Because
urate is the precursor of allantoin, serum urate also was
measured. A weak but statistically significant correlation was
observed between serum urate and allantoin (Spearman’s
rho¼ 0.52; p< 0.001).
Using allantoin formation as a biomarker
Ozone inhalation is well known to cause oxidative stress to
the respiratory tract in humans. Ozone also has a high in-
trinsic reactivity to urate (26), and concentrations of this an-
tioxidant have been shown to be decreased in human nasal
lining fluids after controlled ozone exposures (25). In the latter
study, although urate concentrations decreased by *30%, it
was not possible to address whether this reflected the oxida-
tion of urate in vivo, or its impaired transport onto the lung
surface. In the current study, we observed a significant ozone-
induced elevation of allantoin concentrations in human NLF
samples after a high, but environmentally relevant dose
(200 ppb for 2 h) ozone challenge after a period of vitamin C
and E supplementation, or treatment with placebo (Fig. 4). The
study was a crossover design, with volunteers being exposed in
random order to both ozone and filtered air, with exposures
separated by a period of at least 3 weeks. Baseline, preozone,
and air concentrations did not differ significantly (Wilcoxon
Signed Rank Test) for either urate or allantoin and were sig-
nificantly correlated over the interval between exposures:
Urate preair 36.5 (24.2–69.8) versus preozone 24.5 (14.0–62.7)
FIG. 3. Scatterplot com-
paring allantoin and F2-
isoprostane levels in human
plasma subjected to in vitro
oxidative challenge. Scatter-
plot and best linear fit of
F2-isroprostane and allantoin
levels in plasma samples
exposed to increasing amounts
of hemoglobin. For each vol-
unteer and condition, F2-
isoprostane and allantoin
levels were normalized to con-
trol sample from the same
volunteer not exposed to any
whole-blood lysate. Hemoglo-
bin-induced increases in al-
lantoin show moderately good
correlation to those in total F2-
isoprostanes tested (Pearson
correlation coefficient, 0.69;
p< 0.0001).
FIG. 2. Corrected ion ratio (400–398 m/z) as a function of [1,3-15N2] urate concentration. Human plasma samples were
spiked with increasing amounts of [1,3-15N2] urate. No [
15N]-labeled allantoin internal standard was added. Any 15N-labeled
allantoin detected, therefore, derives entirely from artifactual conversion for [1,3-15N2] urate to allantoin. A corrected ion ratio
of 1 indicates that at least as much 15N-labeled heavy allantoin is present in the sample as is endogenous allantoin. When
[1,3-15N2] urate equivalent to 400mM is added, the ion ratio exceeds unity, suggesting that the extraction artifact in this case
exceeds endogenous allantoin concentrations.
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FIG. 4. Allantoin as a marker of ozone-induced oxidative stress. The molar change (delta) in nasal lavage fluid
urate=allantoin (A, B), ascorbate=dehydroascorbate (B, C), and glutathione=glutathione disulfide concentrations (E, F) during
and after ozone (light grey boxes, with placebo; dark grey boxes, after vitamin supplementation) and filtered air (white boxes)
relative to preexposure concentrations. Data are presented as median values (central line) with the 25th and 75th percentiles
(lower and upper box boundaries) and 95% confidence intervals (whiskers). Comparison of paired air and ozone concentrations
was performed by using the Wilcoxon Signed Rank Test, with the p value indicated. NS, not significantly different from
parallel air response; 1h-E, 1 h into the actual exposure; 0h-PE, immediately after exposure; and 6h-PE, 6 h after exposure.
mM; r¼ 0.61; p¼ 0.03 (Spearman correlation), and allantoin: 1.4
(0.9–2.1) versus preozone 1.2 (0.9–1.9) mM; r¼ 0.60; p¼ 0.03. The
change in concentration of both urate and allantoin at the
prescribed sampling points relative to the preexposure values
are illustrated in Fig. 4A and B and demonstrate that although
no significant loss of urate occurs during or after exposure, a
significant increase in the concentration of allantoin 1 h into
and immediately after exposure, returning to control concen-
trations 6 h after the challenge. Importantly, although the in-
crease in allantoin immediately after exposure was diminished
relative to the 1h-E time point, the individual magnitudes of
change were highly correlated at these two sampling times:
r¼ 0.79; p¼ 0.01. Supplementation for volunteers with oral
antioxidants did not significantly reduce allantoin levels in
NLF, indicating that antioxidant treatment was ineffective in
preventing urate oxidation to allantoin (Fig. 4A and B). Al-
though the evidence for an ozone-induced increase in allantoin
was clear, increases in dehydroascorbate (Fig. 4D) and gluta-
thione disulfide (Fig. 4F) was not observed during or imme-
diately after exposure, with GSSG being largely below the
detection limit in the NLF samples. Evidence was noted of a
loss of NLF ascorbate 0h-PE, after both ozone challenges,
suggesting that oxidation was occurring (Fig. 4C), but this was
not matched by an increase in dehydroascorbate, probably
reflecting the instability of this oxidation product at physiologic
pH (6).
Discussion
Urate is present in blood and other body fluids at concen-
trations up to two orders of magnitude above those of allan-
toin and is easily oxidized to allantoin in vitro under alkaline
conditions. Therefore, artifactual conversion of even a small
percentage of urate to allantoin can lead to gross overesti-
mation of allantoin concentrations. We have introduced a
method to avoid this. The high sensitivity and specificity of
GC=MS allow us to detect low amounts (pmol) of allantoin in
very small samples (25 ml) without the need for solid-phase
extraction. Our method is simple and rapid, with up to 60
samples being routinely processed in the laboratory in 1 day.
We therefore believe that the determination of allantoin can
now become more widely used as a routine method in clinical
studies as a biomarker of oxidative stress.
When our method was applied to human serum samples,
we detected allantoin at concentrations that were signifi-
cantly lower than the values found by using earlier HPLC and
GC=MS methods (Table 2). This is consistent with the as-
sumption that at least some previous methods might be
subject to artifacts. Our values are consistent with those de-
tected by using the more recent HPLC methods by Lagendijk
et al. (21) and Kandar et al. (18), both of which were designed
to remove urate and other interfering substances before
quantification with HPLC, a different approach from the one
that we have taken here. By comparison with these methods,
the method presented here has the advantage that it does not
require any SPE step for the removal of urate before analysis,
reducing time and resource requirement. Furthermore, by
using our method, any loss or degradation during sample
workup will affect the isotope-labeled internal standard in the
same way as endogenous allantoin. The addition of heavy
labeled internal standard before sample extraction therefore
makes our assay highly robust against extraction- and
purification-related artifacts. We used a simple in vitro ex-
periment to generate plasma samples exhibiting a relatively
wide range of oxidative damage. With respect to the physio-
logic relevance of the degree of oxidation observed in this
in vitro setting, it should be noted that it has previously
been reported that F2-isoprostane levels in certain pathologic
situations can be more than twice as high as those of well-
matched controls (e.g., ref. 1). This indicates that the highest
degree of in vitro oxidative damage imposed in our plasma
samples (*300%) is comparable to levels that can indeed be
observed in vivo under certain conditions, at least as far as F2-
isoprostanes are concerned. We acknowledge that this simple
in vitro paradigm cannot predict the performance of allantoin
relative to F2-isoprostanes in the context of elevated in vivo
oxidative stress. However, the relatively good correlation of
allantoin with the more-established biomarker over the whole
range of oxidative damage observed suggests that allantoin,
at least in this in vitro setting, is a robust marker of oxidative
damage, comparable to F2-isoprostanes.
Having established and validated a method for the de-
termination of allantoin in serum and plasma, free from ar-
tifactual sample oxidation, we next examined allantoin
concentrations in NLF samples obtained from healthy sub-
jects exposed to ozone, with and without supplementation
with vitamin C and E. Previous work demonstrated ozone-
dependent oxidation of plasma (9) and nasal-lining fluid urate
ex vivo (16), as well as evidence of decreased urate concen-
trations in vivo (25). Whereas previous studies demonstrated a
loss of urate during and immediately after ozone exposure, in
Table 2. Comparison of This Study with Previous
Studies Measuring Allantoin in Human Subjects
Method Ref. number
No. of
subjects Allantoin (mM)
HPLC 12 2 7.5 4.6
HPLC 10 7 18.6 3.8
HPLC 20 99 2.4 0.6
HPLC 21 18 12.4 20.6
HPLC 18 171 15.7 7.9
HPLC 19 Male (180) 16.7 8.3
Female (145) 15.8 7.2
HPLC 3 40 20.9 3.1
HPLC 16 19 20.3 8.1
HPLC 15 24 22 12
HPLC 14 30 4.67 2.99
HPLC 4 6 3.5 1.0
GC=MS 27 Male (56) 13.4 [7.4–46.8]a
Female (78) 10.8 [3.7–31.2]a
GC=MS 34 15 13.6 6.3
GC=MS 32 35 12.6 6.3
GC=MS 33 21 15.9 6.9
GC=MS This study Male (49) 2.77 (0.92–8.25)b
Female (49) 2.18 (0.76–9.26)b
Enzymatic 26 30 8.2 3.1
Values listed for each study are baseline levels established for
healthy controls by using various methods and published in the
literature. Values are listed as mean SD when such data were
reported in the original publication.
aValues in square brackets are 95% confidence intervals for mean
baseline levels.
bValues in brackets are 5th and 95th percentiles for median values.
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the current study, no such loss was apparent. The evidence
that allantoin concentrations increased at these times, how-
ever, illustrates that the loss of urate might be being masked
by rapid-repletion kinetics into the nasal-lining fluids after the
sequential lavages.
Interestingly, induction of in vivo oxidation of urate to al-
lantoin in the presence of ozone was much more robust than
that of either ascorbate to dehydroascorbate, or glutathione to
glutathione disulfide in the same samples. This was the case
for ascorbate, even after vitamin C supplementation, which
has previously been shown to induce a transient three- to
fourfold increase in nasal-lining fluid ascorbate concentra-
tions (4). This suggests that urate may be a more relevant
antioxidant in this particular setting, a result consistent with
both its rapid reaction rate with ozone (26) and its relatively
high abundance compared with other low-molecular-weight
antioxidants in NLF as well as serum (31, 32), even after
supplementation with ascorbate (26). Given this dominant
role of urate relative to ascorbate and glutathione in the NLF,
the observation that supplementation of volunteers with oral
ascorbate before ozone exposure is ineffective in preventing
urate oxidation to allantoin is perhaps not surprising. The
direct evidence of urate oxidation by ozone in the nasal-lining
fluids also raises the possibility that the upper airways may
effectively scrub a significant proportion of inhaled ozone,
limiting its interaction with more-sensitive distal lung cells
(9). Together these data highlight the utility of allantoin as a
biomarker of urate oxidation in vivo, providing a tool for es-
timating the ozone-scavenging capacity of the upper airway
as well as a marker of oxidative damage in plasma and serum.
The method described here should allow the more frequent
use of allantoin measurements to assess oxidative damage
accurately in vivo.
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